Business Model & Strategy
Business Model
OCT is an innovative and growing UK-quoted bitoech company developing a portfolio of prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide, bringing value to people living with debilitating conditions such as CIPN, IBS, Trigeminal Neuralgia and cancer.
-
We understand and attach importance to the therapeutic potential of cannabinoids in improving the lives of people living with chronic pain and cancer who deserve clinically-proven, safe and effective treatments.
We are a pre-revenue, milestone driven biotech company and as such, we focus on moving our programmes through their clinical development milestones to grow value in our business. Our programmes are focused on harnessing the power of cannabinoids to develop new prescription medicines for people in need.
Strategy
OCTP has established a pipeline of three types of cannabinoid compounds, from which it is developing medicines that target the endocannabinoid system and address significant unmet medical needs including rare diseases:
Synthesized phytocannabinoids, where the cannabinoid found in the plant is chemically reproduced (pCBs) e.g. CBD, THC
Chemically modified pCBs with improved drug-like characteristics, and;
Novel chemical entities (NCEs) which are not cannabinoids but behave like them.
-
This three-pronged strategy enables us to balance risk, value and time to market, whilst ensuring market exclusivity and strong patent protection around all our key activities.
We have developed a proprietary library of almost 500 synthetic cannabinoid derivatives including 14 patent families, providing a source for further drug candidates to enter our pipeline. The library of compounds is screened by academic or commercial partners in disease model assays. The chemical modification of the cannabinoid creates a new compound with the potential for protection under composition of matter patents that we believe we can use to target common indications in addition to rare diseases.
Due to the highly patentable nature of our derivative compounds, we believe that we can target a wide range of pain-related indications with a traditional patent protection strategy. In addition, by also pusuing an orphan indication strategy, we can utilise unmodified pCBs and other off-patent compounds to target a group of rare diseases that would not otherwise be approached, opening up the possibility of new approved medicines for people currently living with these conditions .
We may also in-licence any of the three types of compounds we have described. In-licensing drug candidates that have passed one or more stages in development provides an opportunity to advance our drug pipeline more quickly. In-licensing can also be used to diversify a drug pipeline and to target both large and orphan indications.
Company Information
OCT is incorporated under the laws of England and Wales under the Companies Act 2006 and the company number 13179529. The Company’s main country of operations is the United Kingdom, where it is headquartered.
Company
presentation
